Some investors asked questions on the investor interaction platform: public data show that since November, more than 100 clinical new drugs have been approved in China, of which nearly seven have become antitumor drugs. Are there any representative anti-tumor products or projects under research? Are there approved new drugs? How’s it going? thank you
Shanghai Pharmaceuticals Holding Co.Ltd(601607) (601607. SH) said on the investor interaction platform on January 5 that the company currently has more than 35 innovative drugs under research, is in the key clinical registration and involves the tumor field, and has I036 and I036 for the treatment of Ewing’s sarcoma (the mortality of teenagers is high, and there is a lack of therapeutic drugs at present) BCD-100 introduced from BioCad, Russia, and the anti-tumor small molecule sph6162 of the first overseas equity license out announced in October.
(Daily Economic News)
